Comparison of etanercept and infliximab
| Etanercept | Infliximab | |
|---|---|---|
| *Costs based on a dose that does not exceed a single vial. An additional vial doubles the cost. | ||
| Licensed indications | Polyarticular JIA failing to respond to, or intolerant of, methotrexate | Not licensed |
| Half life | 70 hours | 200 hours |
| Dose | 0.4 mg/kg (max 25 mg) twice weekly | 3 mg/kg at weeks 0, 2, 6, 14, and eight weekly thereafter |
| Route of administration | Subcutaneous injection | Intravenous infusion |
| Side effects | Risk of sepsis | Risk of sepsis, tachyphylaxis |
| Cost of vials | 25 mg vial: £75 | 100 mg vial: £395 + VAT |
| Cost per year* | £7800 | £4177 |